{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:21:55Z","timestamp":1772526115764,"version":"3.50.1"},"reference-count":72,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamadermatol.2018.3186","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:05:08Z","timestamp":1538571908000},"page":"1292","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis"],"prefix":"10.1001","volume":"154","author":[{"given":"Gabriel","family":"Torbahn","sequence":"first","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidelore","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Technical University of Munich, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerta","family":"R\u00fccker","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"Division of General Practice and Family Medicine, Department of Health Services Research, University of Oldenburg, Oldenburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Bischoff","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Freitag","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Dersch","sequence":"additional","affiliation":[{"name":"National Reference Centre for Borrelia, Bavarian Health and Food Safety Authority, Oberschlei\u00dfheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Fingerle","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Motschall","sequence":"additional","affiliation":[{"name":"Division of General Practice and Family Medicine, Department of Health Services Research, University of Oldenburg, Oldenburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg J.","family":"Meerpohl","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Schmucker","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"doi180046r1","doi-asserted-by":"crossref","first-page":"w13725","DOI":"10.4414\/smw.2013.13725","article-title":"Tick related diseases in Switzerland, 2008 to 2011.","volume":"143","author":"Altpeter","year":"2013","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"doi180046r2","first-page":"1","article-title":"Surveillance for Lyme disease\u2014United States, 1992-2006.","volume":"57","author":"Bacon","year":"2008","journal-title":"MMWR Surveill Summ"},{"issue":"20","key":"doi180046r3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJM199511163332004","article-title":"An epidemiologic study of Lyme disease in southern Sweden.","volume":"333","author":"Berglund","year":"1995","journal-title":"N Engl J Med"},{"key":"doi180046r4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000213069","article-title":"Epidemiology of Lyme borreliosis.","volume":"37","author":"Hub\u00e1lek","year":"2009","journal-title":"Curr Probl Dermatol"},{"issue":"8","key":"doi180046r5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1469-0691.12532","article-title":"Lyme borreliosis caused by diverse genospecies of Borrelia burgdorferi sensu lato in northeastern China.","volume":"20","author":"Ni","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"doi180046r6","first-page":"74","article-title":"An estimate of Lyme borreliosis incidence in Western Europe.","volume":"39","author":"Sykes","year":"2017","journal-title":"J Public Health (Oxf)"},{"issue":"22-23","key":"doi180046r7","first-page":"941","article-title":"The outcome of Lyme borreliosis in children.","volume":"111","author":"Aberer","year":"1999","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"doi180046r8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JCM.34.1.1-9.1996","article-title":"Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans.","volume":"34","author":"Aguero-Rosenfeld","year":"1996","journal-title":"J Clin Microbiol"},{"issue":"10","key":"doi180046r9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s100960050381","article-title":"Incidence of Lyme borreliosis in the W\u00fcrzburg region of Germany.","volume":"18","author":"Huppertz","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9814","key":"doi180046r10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","article-title":"Lyme borreliosis.","volume":"379","author":"Stanek","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"doi180046r11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2340\/00015555-1549","article-title":"The many faces of solitary and multiple erythema migrans.","volume":"93","author":"Eriksson","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi180046r12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00105-011-2256-0","article-title":"The variable spectrum of cutaneous Lyme borreliosis: diagnosis and therapy","volume":"63","author":"Hofmann","year":"2012","journal-title":"Hautarzt"},{"issue":"6","key":"doi180046r13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-136-6-200203190-00012","article-title":"Recognition and treatment of erythema migrans: are we off target?","volume":"136","author":"Nadelman","year":"2002","journal-title":"Ann Intern Med"},{"issue":"18","key":"doi180046r14","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMcp1314325","article-title":"Clinical practice: Lyme disease.","volume":"370","author":"Shapiro","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"doi180046r15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-136-6-200203190-00005","article-title":"Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.","volume":"136","author":"Smith","year":"2002","journal-title":"Ann Intern Med"},{"issue":"1","key":"doi180046r16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1469-0691.2010.03175.x","article-title":"Lyme borreliosis: clinical case definitions for diagnosis and management in Europe.","volume":"17","author":"Stanek","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"doi180046r17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"doi180046r18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000213070","article-title":"Clinical manifestations and diagnosis of Lyme borreliosis.","volume":"37","author":"Strle","year":"2009","journal-title":"Curr Probl Dermatol"},{"issue":"6","key":"doi180046r19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/eurpub\/ckv091","article-title":"The burden of Lyme borreliosis expressed in disability-adjusted life years.","volume":"25","author":"van den Wijngaard","year":"2015","journal-title":"Eur J Public Health"},{"issue":"5","key":"doi180046r20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1001\/jamadermatol.2016.5538","article-title":"Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013.","volume":"153","author":"Karimkhani","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi180046r21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00003495-199957020-00003","article-title":"Systematic review of the treatment of early Lyme disease.","volume":"57","author":"Loewen","year":"1999","journal-title":"Drugs"},{"issue":"6","key":"doi180046r22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/0128071-200809060-00002","article-title":"Skin manifestations of lyme borreliosis: diagnosis and management.","volume":"9","author":"M\u00fcllegger","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"8728","key":"doi180046r23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/0140-6736(90)93103-V","article-title":"Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis.","volume":"336","author":"Dattwyler","year":"1990","journal-title":"Lancet"},{"issue":"2","key":"doi180046r24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1128\/AAC.40.2.468","article-title":"Clarithromycin in treatment of early Lyme disease: a pilot study.","volume":"40","author":"Dattwyler","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"doi180046r25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0732-8893(95)00027-8","article-title":"Detection of Borrelia burgdorferi DNA by polymerase chain reaction in the urine and breast milk of patients with Lyme borreliosis.","volume":"21","author":"Schmidt","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"doi180046r26","first-page":"668","article-title":"Penicillin V treatment in erythema migrans can give a false security","volume":"103","author":"Wahlberg","year":"2006","journal-title":"Lakartidningen"},{"issue":"15","key":"doi180046r27","first-page":"1681","article-title":"[First-choice treatment for erythema migrans is still penicillin]","volume":"128","author":"Eliassen","year":"2008","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"9","key":"doi180046r28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1586\/14787210.2014.940900","article-title":"Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.","volume":"12","author":"Cameron","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"60","key":"doi180046r29","first-page":"925","article-title":"Lyme disease part 2: clinic and treatment","volume":"2","author":"Evison","year":"2006","journal-title":"Rev Med Suisse"},{"key":"doi180046r30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12883-015-0501-3","article-title":"Methodological quality of guidelines for management of Lyme neuroborreliosis.","volume":"15","author":"Dersch","year":"2015","journal-title":"BMC Neurol"},{"issue":"11","key":"doi180046r31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"doi180046r32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13643-016-0251-3","article-title":"Efficacy and safety of pharmacological agents in the treatment of erythema migrans in early Lyme borreliosis-systematic review protocol.","volume":"5","author":"Torbahn","year":"2016","journal-title":"Syst Rev"},{"key":"doi180046r35","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis.","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"7","key":"doi180046r36","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis.","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"doi180046r37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3, rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"doi180046r38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0272989X13487604","article-title":"Evidence synthesis for decision making 1: introduction.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"5","key":"doi180046r39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"4","key":"doi180046r40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory.","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"25","key":"doi180046r41","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? comparing two approaches to multi-arm studies in network meta-analysis.","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat Med"},{"issue":"7","key":"doi180046r43","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Trying to be precise about vagueness.","volume":"26","author":"Senn","year":"2007","journal-title":"Stat Med"},{"issue":"1","key":"doi180046r46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jrsm.1143","article-title":"Automated drawing of network plots in network meta-analysis.","volume":"7","author":"R\u00fccker","year":"2016","journal-title":"Res Synth Methods"},{"issue":"24","key":"doi180046r47","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases.","volume":"20","author":"Unnebrink","year":"2001","journal-title":"Stat Med"},{"issue":"1","key":"doi180046r48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.amjmed.2009.05.011","article-title":"Subjective symptoms after treatment of early Lyme disease.","volume":"123","author":"Cerar","year":"2010","journal-title":"Am J Med"},{"issue":"3","key":"doi180046r49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/cid\/cis402","article-title":"Treatment of erythema migrans with doxycycline for 10 days versus 15 days.","volume":"55","author":"Stupica","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"doi180046r50","doi-asserted-by":"publisher","first-page":"e0136600","DOI":"10.1371\/journal.pone.0136600","article-title":"Correlation of culture positivity, PCR positivity, and burden of borrelia burgdorferi sensu lato in skin samples of erythema migrans patients with clinical findings.","volume":"10","author":"Stupica","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"doi180046r51","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000090657","article-title":"Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin.","volume":"212","author":"Aberer","year":"2006","journal-title":"Dermatology"},{"issue":"3","key":"doi180046r52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s150100050069","article-title":"Comparison of azithromycin and doxycycline in the treatment of erythema migrans.","volume":"28","author":"Barsic","year":"2000","journal-title":"Infection"},{"issue":"9","key":"doi180046r53","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-124-9-199605010-00002","article-title":"Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial.","volume":"124","author":"Luft","year":"1996","journal-title":"Ann Intern Med"},{"issue":"3","key":"doi180046r54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/AAC.39.3.661","article-title":"Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans.","volume":"39","author":"Luger","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"doi180046r55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/0002-9343(92)90270-L","article-title":"Treatment of early Lyme disease.","volume":"92","author":"Massarotti","year":"1992","journal-title":"Am J Med"},{"issue":"4","key":"doi180046r56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7326\/0003-4819-117-4-273","article-title":"Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease.","volume":"117","author":"Nadelman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"1","key":"doi180046r57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7326\/0003-4819-99-1-22","article-title":"Treatment of the early manifestations of Lyme disease.","volume":"99","author":"Steere","year":"1983","journal-title":"Ann Intern Med"},{"issue":"2","key":"doi180046r58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01710737","article-title":"Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.","volume":"21","author":"Strle","year":"1993","journal-title":"Infection"},{"issue":"6","key":"doi180046r59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF01728915","article-title":"Azithromycin versus penicillin V for the treatment of early Lyme borreliosis.","volume":"21","author":"Weber","year":"1993","journal-title":"Infection"},{"issue":"9","key":"doi180046r60","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-138-9-200305060-00005","article-title":"Duration of antibiotic therapy for early Lyme disease: a randomized, double-blind, placebo-controlled trial.","volume":"138","author":"Wormser","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"doi180046r61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF01780662","article-title":"Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis.","volume":"24","author":"Breier","year":"1996","journal-title":"Infection"},{"issue":"4","key":"doi180046r62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2340\/0001555572297300","article-title":"Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.","volume":"72","author":"Hansen","year":"1992","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi180046r63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/jac\/30.4.543","article-title":"Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin.","volume":"30","author":"Strle","year":"1992","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"doi180046r64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF01641422","article-title":"A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis.","volume":"18","author":"Weber","year":"1990","journal-title":"Infection"},{"key":"doi180046r65","article-title":"Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice: a randomized controlled trial with a 1-year follow-up","author":"Eliassen","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"doi180046r66","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.diagmicrobio.2018.01.025","article-title":"Is the risk of early neurologic Lyme borreliosis reduced by preferentially treating patients with erythema migrans with doxycycline?","volume":"91","author":"Strle","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"doi180046r67","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/ene.2015.22.issue-9","article-title":"Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis\u2014a systematic review.","volume":"22","author":"Dersch","year":"2015","journal-title":"Eur J Neurol"},{"key":"doi180046r68","first-page":"CD006978","article-title":"Antibiotics for the neurological complications of Lyme disease.","volume":"12","author":"Cadavid","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"doi180046r69","first-page":"Doc14","article-title":"Cutaneous Lyme borreliosis: guideline of the German Dermatology Society.","volume":"15","author":"Hofmann","year":"2017","journal-title":"Ger Med Sci"},{"issue":"16","key":"doi180046r71","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1001\/jama.2016.2884","article-title":"Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review.","volume":"315","author":"Sanchez","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"doi180046r72","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2471\/BLT.16.174326","article-title":"Use of network meta-analysis in clinical guidelines.","volume":"94","author":"Kanters","year":"2016","journal-title":"Bull World Health Organ"},{"key":"doi180046r33","unstructured":"World Health Organization. International Clinical Trials Registry Platform. http:\/\/www.who.int\/ictrp\/search\/en. Accessed July 2018."},{"key":"doi180046r34","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration Version 5.1.0. Chapter 9: analysing data and undertaking meta-analyses by DeeksJJ, HigginsJPT, AltmanDG. https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_analysing_data_and_undertaking_meta_analyses.htm. Updated March 2011. Accessed December 16, 2017."},{"key":"doi180046r42","unstructured":"German Borreliosis Society. Diagnosis and treatment of Lyme borreliosis. http:\/\/www.borreliose-gesellschaft.de\/Texte\/Leitlinien.pdf. Published 2011. Accessed July 5, 2018."},{"key":"doi180046r44","unstructured":"Netmeta. Network meta-analysis using frequentist methods by R\u00fcckerG, SchwarzerG, KrahnU, KoenigJ. https:\/\/CRAN.R-project.org\/package=netmeta. Updated 2017. Accessed December 16, 2017."},{"key":"doi180046r45","unstructured":"R Core Team. R Foundation for Statistical Computing Vienna, Austria, 2017. R: a language and environment for statistical computing. https:\/\/www.R-project.org\/. Accessed December 16, 2017."},{"key":"doi180046r70","unstructured":"National Institute for Health and Care Excellence (NICE). National Guideline Centre. Lyme disease: diagnosis and management. Evidence review for the management of erythema migrans. https:\/\/www.nice.org.uk\/guidance\/ng95\/evidence\/d-management-of-erythema-migrans-pdf-4792271010. Published April 2018. Accessed July 05, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2705272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:27:59Z","timestamp":1761110879000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.3186"}},"subtitle":["A Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.3186","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}